HIRSCHFELD v. BECKERLE

CourtDistrict Court, D. New Jersey
DecidedSeptember 27, 2019
Docket3:18-cv-14796
StatusUnknown

This text of HIRSCHFELD v. BECKERLE (HIRSCHFELD v. BECKERLE) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
HIRSCHFELD v. BECKERLE, (D.N.J. 2019).

Opinion

*FOR PUBLICATION*

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY ___________________________________ : MARC HIRSCHFELD, : : Plaintiff, : Civil Action No. 18-14796 (FLW) (DEA) : v. : : OPINION MARY C. BECKERLE, D. SCOTT : DAVIS, IAN E.L. DAVIS, JENNIFER A. : DOUDNA, ALEX GORSKY, MARK B. : McCLELLAN, ANNE M. MULCAHY, : WILLIAM D. PEREZ, CHARLES : PRINCE, A. EUGENE WASHINGTON, : RONALD A. WILLIAMS, : : Defendants, : and : : JOHNSON & JOHNSON, : : Nominal Defendant. : ___________________________________ :

WOLFSON, Chief Judge: Presently before the Court is a motion by nominal Defendant Johnson & Johnson (“Johnson & Johnson”) and joined by Individual Defendants Mary C. Beckerle, D. Scott Davis, Ian E. L. Davis, Jennifer A. Doudna, Alex Gorsky, Mark B. McClellan, Anne M. Mulcahy, William D. Perez, Charles Prince, A. Eugene Washington, and Ronald A. Williams (“Individual Defendants”) (together, with Johnson & Johnson, “Defendants”),1 to dismiss the shareholder derivative complaint of Plaintiff Marc Hirschfeld (“Plaintiff”) pursuant to Federal Rule of Civil

1 Johnson & Johnson filed a formal motion to dismiss, while Individual Defendants submitted a letter joining Johnson & Johnson’s motion. ECF No. 20-1. Procedure 12(b)(6). In this shareholder derivative litigation, Plaintiff, representing other similarly situated investors of Johnson & Johnson’s stock, alleges that Individual Defendants— members of Johnson & Johnson’s Board of directors—violated their fiduciary duties.

Specifically, Plaintiff maintains that Individual Defendants failed to prevent Johnson & Johnson from continuing to sell talc-based body powders, despite knowledge of research allegedly linking perineal talc application to ovarian cancer and tests allegedly indicating that Johnson & Johnson’s talc contained asbestos or asbestos-like fibers. Defendants move to dismiss the Complaint on the basis that Plaintiff failed to make a pre-suit demand on Johnson & Johnson’s Board of Directors, as is required by the New Jersey Business Corporation Act (“NJBCA”), N.J.S.A. 14A:3-6.3, and alternatively, even if that statute were inapplicable, Plaintiff has failed to adequately plead that a demand would have been futile. For the reasons stated herein,

Defendants’ motion is GRANTED, and Plaintiff's claims are dismissed without prejudice. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY The facts are taken from the Complaint and assumed to be true for purposes of this motion. This action arises from the same factual underpinnings that are involved in thousands of cases in multiple courts across the country. Compl. at ¶ 10. Plaintiff alleges that since as early as 1971, Johnson & Johnson has been aware of tests indicating that the talc used in certain of its

products contained asbestos or asbestos-like fibers. Id. at ¶ 5. Since as early as 1982, Johnson & Johnson allegedly has been aware of credible scientific studies concluding that a woman’s repeated use of talc-based body powders in her genital region significantly increases her risk of developing ovarian cancer. Id. at ¶ 6. Despite this knowledge, Johnson & Johnson allegedly continues to sell its talc-based Baby Power and Shower to Shower products and disavows the presence of any asbestos contained in its products, or that there is any link between perineal talc usage and ovarian cancer. Id. According to the Complaint, based on this willful conduct, the Individual Defendants (or their predecessors on the Board) directly violated their fiduciary obligations by: (i) refusing to place any cancer-related warning on Johnson & Johnson Baby Powder or Shower to Shower products; (ii) continuing to market such products as safe, and

promoting the perineal use of those products by women; (iii) actively lobbying against Federal Drug Administration testing of asbestos levels in cosmetic talc products; (iv) forming a task force within a trade association to which Johnson & Johnson belonged to defend talc usage and undermine studies showing that it posed a public health risk; and (v) terminating research that it initiated and funded if the studies did not support Johnson & Johnson’s claim that talc was safe and/or not linked to an increased risk of ovarian cancer. Id. at ¶ 9. Plaintiff filed this suit on October 9, 2018, bringing one count for breach of fiduciary duties by Individual Defendants. In the Complaint, Plaintiff frankly admits that he “has not made

a demand on the Board of Directors of the Company to file a suit asserting the claims specified herein” because “[s]uch a demand would be futile and useless.” Id at ¶ 99.2 Subsequently, Defendants filed the present motion, arguing that Plaintiff’s claims must be dismissed because the NJBCA eliminated the concept of demand futility, and, furthermore, Plaintiff’s demand futility allegations are inadequate. II. LEGAL STANDARD

2 According to Defendants, another shareholder previously made a demand on Johnson & Johnson’s Board with respect to matters similar to those alleged in the Complaint. See Decl. of D. Wong Yang ¶ 3. In response to that demand letter, the Board retained independent legal counsel, “to investigate, review, and analyze the facts and circumstances surrounding the allegations raised in the demand letter, as well as any subsequently received demands or shareholder derivative lawsuits making similar allegations.” Id. Under Fed. R. Civ. P. 12(b)(6), a complaint may be dismissed for “failure to state a claim upon which relief can be granted.” Fed. R. Civ. P. 12(b)(6). When reviewing a motion to dismiss on the pleadings, courts “accept all factual allegations as true, construe the complaint in the light

most favorable to the plaintiff, and determine whether, under any reasonable reading of the complaint, the plaintiff may be entitled to relief.” Phillips v. Cnty. of Allegheny, 515 F.3d 224, 233 (3d Cir. 2008) (quotations omitted). Under such a standard, the factual allegations set forth in a complaint “must be enough to raise a right to relief above the speculative level.” Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007). Indeed, “the tenet that a court must accept as true all of the allegations contained in a complaint is inapplicable to legal conclusions.”

Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009). “[A] complaint must do more than allege the plaintiff's entitlement to relief. A complaint has to ‘show’ such an entitlement with its facts.” Fowler v. UPMC Shadyside, 578 F.3d 203, 211 (3d Cir. 2009). However, Rule 12(b)(6) only requires a “short and plain statement of the claim showing that the pleader is entitled to relief” in order to “give the defendant fair notice of what the . . .

claim is and the grounds upon which it rests.” Twombly, 550 U.S. at 555. The complaint must include “enough factual matter (taken as true) to suggest the required element. This does not impose a probability requirement at the pleading stage, but instead simply calls for enough facts to raise a reasonable expectation that discovery will reveal evidence of the necessary element.” Phillips, 515 F.3d at 234 (citation and quotations omitted); Covington v. Int’l Ass’n of Approved Basketball Officials, 710 F.3d 114, 118 (3d Cir. 2013) (“[A] claimant does not have to set out in

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Caminetti v. United States
242 U.S. 470 (Supreme Court, 1917)
Landreth Timber Co. v. Landreth
471 U.S. 681 (Supreme Court, 1985)
United States v. Ron Pair Enterprises, Inc.
489 U.S. 235 (Supreme Court, 1989)
United States v. Smith
499 U.S. 160 (Supreme Court, 1991)
Kamen v. Kemper Financial Services, Inc.
500 U.S. 90 (Supreme Court, 1991)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
In Re Merck & Co. Securities & ERISA Litigation
493 F.3d 393 (Third Circuit, 2007)
Allen Ex Rel. Allen & Brock v. Ferrera
540 S.E.2d 761 (Court of Appeals of North Carolina, 2000)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Dunn v. Ceccarelli
489 S.E.2d 563 (Court of Appeals of Georgia, 1997)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
Winberry v. Salisbury
74 A.2d 406 (Supreme Court of New Jersey, 1950)
Speetjens v. Malaco Inc.
929 So. 2d 303 (Mississippi Supreme Court, 2006)
NJ Dist. Ct. Assoc., Inc. v. NJ Sup. Ct.
501 A.2d 596 (New Jersey Superior Court App Division, 1985)
In Re PSE & G Shareholder Litigation
801 A.2d 295 (Supreme Court of New Jersey, 2002)
Matter of Prudential Ins. Co. Litig.
659 A.2d 961 (New Jersey Superior Court App Division, 1995)

Cite This Page — Counsel Stack

Bluebook (online)
HIRSCHFELD v. BECKERLE, Counsel Stack Legal Research, https://law.counselstack.com/opinion/hirschfeld-v-beckerle-njd-2019.